2017. The testosterone replacement Axiron generated over $48 million dollars in profit in 2011.
Coined “The Wittert Study”, after Gary Wittert who is the leader of this study, this novel study is banking on being the first of many to address the worldwide epidemic of type 2 diabetes using
testosterone treatment as a preventativeXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX